Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Cardiol Therapeutics ( (TSE:CRDL) ) has provided an update.
Cardiol Therapeutics announced its participation in the Oppenheimer 35th Annual Healthcare Life Sciences Conference, showcasing its ongoing commitment to advancing treatments for heart disease. The company has US FDA authorization for clinical trials on its lead drug, CardiolRx™, and is actively conducting studies for recurrent pericarditis and acute myocarditis. This participation underscores Cardiol’s strategic direction and potential impact on the life sciences industry, especially with its innovative approaches to heart disease treatment.
More about Cardiol Therapeutics
Cardiol Therapeutics Inc. is a clinical-stage life sciences company that focuses on developing anti-inflammatory and anti-fibrotic therapies for heart disease. Its lead product, CardiolRx™, is a cannabidiol oral solution in clinical development for treating heart conditions such as recurrent pericarditis and acute myocarditis. The company is also developing a novel drug formulation, CRD-38, for heart failure.
YTD Price Performance: 2.92%
Average Trading Volume: 371,998
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $112.9M
See more data about CRDL stock on TipRanks’ Stock Analysis page.
